Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SARCLISA safely and effectively. See full prescribing information for SARCLISA. SARCLISA® (isatuximab-irfc) injection, for intravenous use Initial U.S. Approval: 2020
Medication labelWhy this: Advisory · dailymed-prescription
SARCLISA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).
- generic_name
- isatuximab
- product_names
- isatuximab
- ndc
- 0024-0654, 0024-0656, 0024-0654-01, 0024-0656-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en